BeiGene, Ltd.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John V. Oyler
- Full Time Employees
- 10,600
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Cambridge Parkway Cambridge MA United States of America 02142
- IPO Date
- Feb 3, 2016
- CIK
- 0001651308
- Website
- beigene.com
- Similar Companies
- Business
- BeOne Medicines Ltd, formerly BeiGene Ltd (BGNE), develops and commercializes innovative oncology therapeutics, including molecularly targeted therapies and immuno-oncology drugs for cancer treatment; its core products comprise BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor approved for mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström's macroglobulinemia; TEVIMBRA (tislelizumab), a PD-1 monoclonal antibody approved for Hodgkin lymphoma, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma and extensive-stage small cell lung cancer in various combinations with chemotherapy; and in-licensed products such as XGEVA, KYPROLIS and BLINCYTO from Amgen for commercialization primarily in China. The company advances a broad pipeline addressing approximately 80 percent of global cancer incidence through internal discovery, clinical development and strategic partnerships, with modalities including antibody-drug conjugates, targeted degraders and small molecules. BeOne Medicines operates in more than 65 markets across six continents, with a significant presence in China, the United States and Europe; it maintains administrative centers in Cambridge, Massachusetts; Basel, Switzerland; and Beijing, China. Founded in 2010 by John V. Oyler and Xiaodong Wang and headquartered in Cambridge, Massachusetts, the company conducts all first-in-human phase 1 trials of internal assets in Australia and enrolls patients from over 45 countries in its global clinical programs. In recent developments, BeOne Medicines completed its rebranding from BeiGene Ltd announced on November 14, 2024, changed its U.S. subsidiary name to BeOne Medicines USA, Inc. effective March 17, 2025, shifted its stock ticker to ONC in January 2025 and redomiciled from the Cayman Islands to Basel, Switzerland in May 2025 pending shareholder approval; it opened a flagship $800 million U.S. biologics manufacturing and clinical R&D facility in Princeton, New Jersey in July 2024 to enhance supply chain resiliency and production scale; secured FDA approval for TEVIMBRA expansions in esophageal squamous cell carcinoma in March 2025 and positive CHMP opinion for small cell lung cancer in March 2025; reported positive phase 3 topline results for sonrotoclax in chronic lymphocytic leukemia and ZIIHERA as a HER2-targeted therapy in late 2025; exercised an option for the B7H4-directed ADC DB1312 from Duality Biologics worth up to $1.3 billion in late 2024; and announced first quarter 2025 revenues of $1.1 billion with BRUKINSA sales up 62% to $792 million.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
President Trump demands drugmakers slash prices within 60 days
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation Innovation
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices +
BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
BeiGene to Announce First Quarter 2025 Financial Results on May 7
BeiGene initiated with an Outperform at RBC Capital
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025